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The structure of the N-terminal actin-binding domain of human
dystrophin and how mutations in this domain may cause
Duchenne or Becker muscular dystrophy
Fiona LM Norwood1†, Andrew J Sutherland-Smith1†*, Nicholas H Keep1,2
and John Kendrick-Jones1
Background: Dystrophin is an essential component of skeletal muscle cells. Its
N-terminal domain binds to F-actin and its C terminus binds to the dystrophin-
associated glycoprotein (DAG) complex in the membrane. Dystrophin is
therefore thought to serve as a link from the actin-based cytoskeleton of the
muscle cell through the plasma membrane to the extracellular matrix. Pathogenic
mutations in dystrophin result in Duchenne or Becker muscular dystrophy. 
Results: The crystal structure of the dystrophin actin-binding domain (ABD) has
been determined at 2.6 Å resolution. The structure is an antiparallel dimer of
two ABDs each comprising two calponin homology domains (CH1 and CH2)
that are linked by a central α helix. The CH domains are both α-helical globular
folds. Comparisons with the structures of utrophin and fimbrin ABDs reveal that
the conformations of the individual CH domains are very similar to those of
dystrophin but that the arrangement of the two CH domains within the ABD is
altered. The dystrophin dimer reveals a change of 72° in the orientation of one
pair of CH1 and CH2 domains (from different monomers) relative to the other
pair when compared with the utrophin dimer. The dystrophin monomer is more
elongated than the fimbrin ABD.
Conclusions: The dystrophin ABD structure reveals a previously
uncharacterised arrangement of the CH domains within the ABD. This
observation has implications for the mechanism of actin binding by dystrophin
and related proteins. Examining the position of three pathogenic missense
mutations within the structure suggests that they exert their effects through
misfolding of the ABD, rather than through disruption of the binding to F-actin.
Introduction
Duchenne muscular dystrophy (DMD) is the most
common serious X-chromosome-linked genetic disorder,
with an approximate incidence of one in 3500 live-born
males. It is now more than ten years since the gene for
DMD was isolated [1,2] and shown to be allelic with that
for Becker muscular dystrophy. The protein encoded by
the gene is called dystrophin [3]. Initially, because of its
size and inferred shape [4], dystrophin was thought to be a
purely structural protein, providing mechanical strength
for the muscle-cell membrane; localisation studies suggest
that this might be one of its roles although its precise cel-
lular function(s) remain to be established. In addition, dys-
trophin has been shown to associate directly with a variety
of intracellular components, such as the actin cytoskeleton
and the dystrophin-associated glycoprotein complex
(DAG) in the plasma membrane [5–8], and indirectly with
extracellular components such as laminin and merosin
[9,10]. Thus dystrophin in a muscle cell acts as a linker
molecule providing continuity between the F-actin-based
subsarcolemmal cytoskeleton and laminin in the extracel-
lular matrix via a glycoprotein complex in the sarcolemma
(plasma membrane; for a review see [11]).
The expression of the gene encoding dystrophin has been
detected in many types of cell, including skeletal, cardiac
and smooth muscle. Full-length dystrophin transcribed
from the muscle (M) promoter translates into a protein of
3685 amino acids with a molecular mass of 427 kDa [3].
On the basis of its primary sequence and homologies with
other molecules, dystrophin has been divided into
domains [4]. The 30 kDa N-terminal domain is the focus
of this work. The large central domain comprises 24 spec-
trin-like three-helix bundle motifs. The C-terminal region
interacts directly with the transmembrane protein β-dys-
troglycan and hence indirectly with the other members of
the dystrophin–glycoprotein complex. It contains several
motifs, which are (from the N to C termini) the WW
domain (characterised by two highly conserved tryptophan
residues), two putative Ca2+ binding EF hands, a ZZ
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domain (a putative zinc-binding motif) and two predicted
α helices (reviewed in [12]).
Improved detection methods have produced extensive
lists of individual disease-causing mutations within the
dystrophin gene. The distribution of large deletions and
duplications is non-random, with clustering around
regions of exons 2–20 and 45–53 (N-terminal domain and
the beginning and end of the helical repeat region, e.g.,
[13]). Point mutations, accounting for the remaining third
of the mutations, are distributed more evenly along the
gene [14], a few of them have been detected in the N-ter-
minal domain. Thus, although defects in dystrophin are
the underlying cause of Duchenne and Becker muscular
dystrophies, the exact pathogenic mechanism involved
remains unclear.
The possibility that the dystrophin N-terminal region
might bind to F-actin was first noticed  through its primary
sequence similarity to the corresponding actin-binding
regions of chicken α-actinin [15,16]. Members of this
‘spectrin superfamily’, which now also contains utrophin,
are proposed to derive from a common ancestor [17–19]
and to contain regions that are structurally and function-
ally analogous, leading to suggestions that members of the
superfamily might be able to complement each other [16].
The sequence from which the actin-binding regions are
proposed to derive is homologous with the smooth muscle
protein calponin and hence has been designated as a
calponin homology (CH) domain [20]. Proteins containing
CH domains include spectrin, α-actinin, dystrophin,
utrophin and fimbrin. Apart from calponin itself and in
SM22 (transgelin), the signalling protein IQGAP and the
proto-oncoprotein Vav with a single CH domain [17],
these domains occur in tandem, each pair represented
once in each actin-binding domain (ABD); the exception
is fimbrin, which has two pairs of CH domains organised
into two ABDs. The N-terminal (CH1) domain from one
protein bears closer resemblance to the equivalent CH1
domain of a homologous protein than to the C-terminal
(CH2) domain of its own molecule.
The crystal structures of the CH2 domain from spectrin
[21,22] and from utrophin [23] revealed that the CH
domain is mainly α-helical, with a core of four helices.
Three of the helices are roughly parallel to each other and
the fourth is approximately perpendicular to the other
three. In addition, the structures of the N-terminal
fimbrin ABD [24] and the ABD from utrophin [25] have
also been determined recently, and again the core CH
domain structure is preserved. The manner in which the
two domains are organised within the ABD, however, is
strikingly different. The fimbrin ABD crystallises as a
monomer with a compact globular structure, whereas
utrophin forms an antiparallel dimer of two ABDs, each
adopting a more elongated dumbell shape.
We present the crystal structure of the human dystrophin
ABD. This study was undertaken for several reasons. Dys-
trophin deficiency is the molecular defect underlying
DMD and this is the first report describing the tertiary
structure of part of this protein. A possible therapeutic
strategy to alleviate muscle-cell damage in DMD patients
is to replace the function of the missing protein with a
molecule that has an equivalent function. The current
interest in utrophin centres on its potential for replacing
dystrophin, which is absent in DMD patients [26], and
therefore the demonstration that their actin-binding
regions are equivalent is important. The position of three
regions of primary sequence involved in actin binding have
been proposed through peptide-binding, sequence compar-
ison and deletion analysis experiments [27–29], although
the tertiary arrangement of these sequences remained
unknown. Disease-causing mutations affecting the N-ter-
minal region [14] might be assumed to produce their dele-
terious effect through modulating this region’s binding to
F-actin in some way. In order to resolve these issues, the
structure of the N-terminal actin-binding region of human
dystrophin has been determined at 2.6 Å resolution.
Results and discussion
The final model comprises four dystrophin ABDs assem-
bled into two dimers within the asymmetric unit. The
N terminus is disordered resulting in a dystrophin ABD
model consisting of residues 9–246. A Ramachandran plot
of mainchain torsion angles (φ,ψ) calculated using the
program MOLEMAN2 [30] reveals that 97% of residues lie
within the favoured region. The average temperature
factors for the protein mainchain, protein sidechain and
solvent atoms are 37.5 Å2, 37.7 Å2, and 38.4 Å2, respectively.
Two dystrophin ABDs assemble into an antiparallel dimer
(approximate dimensions 80 × 50 × 30 Å) with the N-termi-
nal CH1 domain of one monomer in close association with
the C-terminal CH2 domain of the other (Figure 1a). Each
ABD monomer adopts an extended dumbell shape com-
prising the two CH domains connected by an α helix (helix
I, Figure 1b). The CH2 domain is formed from a scaffold of
seven helices (which are shown mapped to the sequence in
Figure 2 and are labelled A–G, as in [21]), with the major
helices A, C, E, and G comprising the core of the domain.
Helices C, E and G are approximately parallel and form a
triple helical bundle; the N-terminal A helix lies perpendic-
ular to this bundle, packing against the C and G helices.
Helices B, D and F are short two and three turn helices that
connect the major structural elements. The CH1 domain
exhibits the same overall fold as the CH2 region. Superpo-
sition of the CH1 and CH2 domains on the core A, C, E
and G helices (55 Cα atoms) results in a root mean square
deviation (rmsd) of 1.4 Å, whereas an overlay using all Cα
atoms within the CH domains (104 Cα atoms) results in a
superposition with an rmsd of 3.7 Å. These comparisons
show that substantial differences exist between the loop
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regions of the CH1 and CH2 domains even though the core
structures of the two domains are very similar. The short B
and D helices are not present in the CH1 domain and are
replaced with loop regions and an extra turn at the N termi-
nus of the E helix. In addition, the CH1 domain has two
residues deleted in the FG loop (between helices F and G)
when compared with the CH2 domain. The regions C-ter-
minal to the core CH fold exhibit quite different conforma-
tions in the two domains. The polypeptide chain extends
from the G helix in CH1 forming helix I connecting the
two CH domains. The C terminus of CH2 contains an
extended region that interacts with the noncrystallographic
symmetry (NCS) C terminus from the other monomer and
packs so that it is perpendicular to the connecting I helices
at the dimer interface. 
The dystrophin and utrophin ABDs share 72% sequence
identity (Figure 2). This high degree of conservation is
reflected in a comparison of the structures of the individ-
ual CH domains. Superposition of the CH1 domains from
dystrophin and utrophin results in an rmsd of 0.87 Å (cal-
culated on 106 Cα atoms), whereas comparison of the
CH2 domains yields an rmsd of 1.06 Å (calculated on 101
Cα atoms). The structural core of CH domains from the
ABDs of other actin-binding proteins is also highly con-
served. Overlays of the CH1 domains from dystrophin and
the N-terminal ABD of fimbrin result in a superposition
with an rmsd of 1.48 Å. The dystrophin CH2 domain
superimposes on the CH2 structures of fimbrin and spec-
trin with an rmsd of 1.12 Å and 0.58 Å, respectively. In
both sets of comparisons the superpositions were calcu-
lated on the A, C, E and G helices (46 Cα atoms only).
The antiparallel quaternary structure of the dystrophin
dimer brings the CH1 domain of one monomer into
contact with the CH2 domain from the other, forming two
domain-swapped CH1–CH2 interfaces. These dimer con-
tacts are supplemented by extensive contacts between
helix I and the corresponding region in the other
monomer, in addition to interactions with the C termini.
Hydrophobic patches formed by residues Val123, Met124,
Ile127, Met128, Ala129, Gly130 and Leu131 on a face of
helix I, and residues Val243 and Ile245 at the C terminus,
are buried upon dimer formation (Figure 3). A total of
2447 Å2 accessible surface area of one monomer is
excluded from solvent at the dimer interface, correspond-
ing to 19% of its total surface area. The shape complemen-
tarity of the dimer interface can be described by
calculation of the gap index value, defined as the ratio of
the gap volume between the monomers and the interface-
accessible surface area [31]. The gap index for the dys-
trophin dimer is 1.5 Å, a value that is indicative of a high
degree of complementarity for the interface compared
with that of many other oligomeric structures analysed by
this algorithm. The shape complementarity and total area
of the interface imply a relatively stable dimer [31]. 
A comparison of the dystrophin and utrophin dimers
reveals a large conformational shift (Figure 4). The trans-
formation is a 72° rigid-body rotation of a CH1–CH2 pair
Research Article  Crystal structure of the dystrophin actin-binding domain Norwood et al. 483
Figure 1
A200
N
B50
C
A150
ACH1
A100
B100
BCH2
BCH1
ACH2
B150
A50
C
N
B200
A200
N
B50
C
A150
BCH2
ACH2
ACH1
B100
A100
BCH1
B150
C
A50
N
B200
N A
C
E
F
G
I
A
B
C
D
E
F
G
CH2
CH1
C
(a) (b)
Structure
Structure of the dystrophin actin-binding domain. (a) Stereoview Cα trace of the dystrophin dimer.  Every tenth residue is highlighted and every
fiftieth numbered. (b) Ribbon diagram of the dystrophin ABD. The ribbon representation is colour ramped from the N terminus (blue) to the C
terminus (red); the helices are labelled.
(from different monomers) relative to the other pair. The
rotation occurs approximately around helix I, although the
relative orientation of the helix is altered. This shift
results in the four CH domains in the dystrophin dimer
adopting a more planar conformation, relative to the
twisted structure of the utrophin dimer. The perturbations
that occur in the rigid-body shift are localised at the end of
the interconnecting helix I (residues 120–124 at the C ter-
minus of CH1 and 133–137 at the N terminus of CH2). 
In the crystal structure of dystrophin the formation of
the dimer positions the two CH2 domains so that the
C-terminal residues of each domain can interact with
each other and the central I helices. The corresponding
interactions cannot occur in utrophin because the CH2
domains are much further apart than they are in dys-
trophin. The total area buried at the dystrophin dimer
interface is 2447 Å2, however, which is a similar value to
that found for utrophin, 2413 Å2. The gap index (as
briefly described above) is smaller for the dystrophin
dimer interface (1.5 Å) than for that of utrophin (1.8 Å).
A greater number of potential hydrogen bonds exist
across the dystrophin dimer interface, with 30 potential
interactions formed, in contrast to the 18 in utrophin.
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Figure 2
Sequence alignment of ABDs from dystrophin,
utrophin, α-actinin, β-spectrin and T-fimbrin
(N-terminal and C-terminal ABDs). The exact
secondary structure of the dystrophin structure
reported here is represented and the ABSs
are indicated by boxed regions. The positions
(residues 54, 168, 171 and 231) where
pathogenic dystrophin mutations occur are
shaded yellow. 
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Figure 3
Stereoview of the dystrophin I helix and 
C-terminal dimer interface.
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These two factors would suggest that the dystrophin
dimer is more stable than utrophin. The majority of
residues in the region of helix I are conserved between
dystrophin and utrophin (Figure 2) and there does not
appear to be an obvious single mechanism for the confor-
mational rearrangement. It is not possible to determine
whether or not the C-terminal interactions present in
dystrophin, but absent in utrophin, are a result of the
dimer structure or contribute to its formation. The sub-
stitution of sulphur with selenium in the methionines of
utrophin, which is necessary for its structure determina-
tion [25], might have contributed to the dimer conforma-
tion observed in that structure. Two of these
methionines in the equivalent positions in helix I of dys-
trophin (residues 124 and 128) are buried within the
structure; between the two I helices of the dimer and the
C-terminal residues. The additional bulk of the sele-
nium atoms might have contributed to structural
rearrangements in this region in utrophin. 
A striking feature of the crystal structure of dimeric dys-
trophin compared with the monomeric fimbrin structure is
the conservation of the interface between the CH1 and
CH2 domains. The dystrophin interface is formed
between CH domains from different monomers, whereas
in fimbrin the structurally homologous interface is formed
with CH1 and CH2 from the same monomer (Figure 4).
Analytical ultracentrifugation and gel filtration experi-
ments have revealed that the dystrophin ABD can exist in
solution as relatively stable monomers or dimers and
during equilibrium centrifugation a monomer–dimer equi-
librium exists (with a relatively weak Kd of approximately
4 µM; FLMN and JK-J, unpublished observations). The
conservation of the CH1–CH2 interface suggests that the
dystrophin ABD might adopt a compact fimbrin-like
structure in its monomeric form whereas the dimeric state
is similar to that found in the crystal structure. This idea
highlights the importance of the linker region between
the CH domains, which was previously revealed by
genetic analysis of mutants of the yeast fimbrin, Sac6p
[32]. The longer linker polypeptide (an additional 13
residues relative to dystrophin; Figure 2) between the CH
domains in the fimbrin N-terminal ABD might favour the
monomeric structural conformation, whereas the shorter
dystrophin/utrophin linker might inhibit the monomer
folding back on itself in the crystal structure. Apart from
dystrophin and utrophin there is no detectable sequence
similarity in this region in the ABDs of related proteins.
The fimbrin ABD crystal structure [24] indicates that con-
formational flexibility can exist in the CH1–CH2 linker
region. Eight residues cannot be located in the electron-
density map as a result of being disordered and a further
seven residues on either side of this region have no
sidechains included in the model. In order for dystrophin
to adopt a similar monomeric structure the linker region
would have to adopt a quite different conformation to that
observed in the crystal structure. In the dystrophin ABD
crystal structure the C terminus of the CH1 domain from
monomer A and the N terminus of the CH2 domain from
monomer B are located in close proximity to one another
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Ribbon representation of (a) dystrophin, (b) utrophin and (c) fimbrin. The molecules were oriented by superposition on all conserved Cα atoms of
the upper CH1–CH2 pair.
(the distance between A123 Cα and B136 Cα is 5.6 Å).
The dystrophin linker region, although shorter than the
fimbrin linker, can span this distance but would require
some unwinding of the interconnecting helix to adopt the
compact fimbrin-like conformation. Current evidence sug-
gests that full-length dystrophin is unlikely to dimerise in
a similar manner to that of the dystrophin ABDs in the
crystal structure. Gel filtration experiments with dys-
trophin-bound to DAG [33], and blot overlay assays using
dystrophin fragments [34] suggest that full-length dys-
trophin is monomeric, although oligomeric as well as
monomeric dystrophin was observed in rotary-shadowed
micrographs [35].
Structural basis of DMD/BMD phenotypes
Solving the structure of the dystrophin ABD makes it pos-
sible to examine the structural basis of some of the muta-
tions detected in Duchenne and Becker muscular
dystrophy patients. Gene rearrangements, comprising large
deletions and duplications, account for two-thirds of the
mutations found in these patients (e.g., see [36]). In addi-
tion, a number of small deletions and missense mutations
have been characterised (reviewed in [14]), some of which
occur in the ABD. These include four missense mutations
and two single-exon deletions in which the reading frame
is maintained. However, the background information sup-
plied on these patients is limited. BMD patients with the
mutations Ala168→Asp and Tyr231→Asn are reported
only as components of a tabulated summary [14]. Most
details are available for a DMD patient with a Leu54→Arg
mutation [37]. This patient is unusual in that he appears to
produce 20% of the normal level of dystrophin; most DMD
patients produce little or none. In addition, the protein is
reported as being of normal size and correctly localised at
the sarcolemma. Despite these findings, the phenotype is
severe. Recently, a new mutation has been reported in a
point mutation database [38]; which is Ala171→Pro in a
BMD patient, and lies only three residues distal to
Ala168→Asp. Several studies have reported deletions of
one or more exons in this region (e.g., see [39]); these are
summarised in a review [40]. In-frame deletions of each of
the single exons 3 (residues 32–62) and 5 (residues 89–119)
are rare. The phenotype resulting from the deletion of
exon 3 is variable (DMD to BMD) and that for exon 5
intermediate to severe. Exon 3 deletion patients have little
detectable protein whereas exon 5 deleted patients have
reduced levels of dystrophin.
Examination of the position of these mutations in the ter-
tiary structure is of interest. The mutation Leu54→Arg in
a DMD patient, is located on a hydrophobic face of the
CH1 domain C helix where its leucine sidechain, in con-
junction with leucines 50, 51, 53 and 57, contributes to the
core of the domain. This region of the C helix packs
against Ala80, Val83 and Leu84 on the hydrophobic
surface of helix E, as well as Ile114 and Trp118 from helix
G (Figure 5a,b). The substitution  Arg54→Leu would be
expected to destabilise the domain fold by the introduc-
tion of a large charged sidechain into this hydrophobic
environment. This residue is conserved as leucine or
isoleucine in CH1 domains (Figure 2), with the exception
of the CH1 domains from human T fimbrin and yeast
Sac6p in which this residue is tyrosine. Both of these pro-
teins contain double ABDs and appear to be more evolu-
tionarily divergent than dystrophin [17].
The other three missense mutations occur in BMD
patients. Ala168→Asp is located on the internal face of
helix C in a hydrophobic pocket formed by Val154 and
Val156, and Trp164 (Figure 5c). An aspartate sidechain
could be accommodated in its most favoured rotamer but
the introduction of a charged residue into an internal
hydrophobic pocket would be expected to destabilise the
protein fold. Ala171 also lies in helix C (Figure 5c); a
mutation to a proline residue would be expected to intro-
duce a kink into the helix [41,42] possibly disrupting the
tertiary fold of the CH2 domain. Tyr231→Asn is located
on the internal surface of helix G (Figure 5c), with the aro-
matic ring packing against the sidechains of Phe200,
Leu213 and Leu234. This mutation results in a sidechain
with decreased steric bulk and hydrophobic nature. A
mutation responsible for suppressing actin-binding at an
equivalent position in yeast fimbrin (Phe381→Cys) has
also been characterised [32]. The location of the mutation
sites within the core of CH domains suggests that these
mutations affect protein folding, and do not replace amino
acid sidechains that are crucial for actin binding. 
Pathogenic in-frame deletions of exons 3 (residues 32–62)
and 5 (residues 89–119; Figure 5d) of the dystrophin gene
have also been characterised [40]. Removal of these large
regions of the ABD would be expected to have a cata-
strophic effect on protein folding and function.
Mechanism of actin binding
Attempts have been made to define the residues in the
dystrophin ABD involved in binding to F-actin, and three
areas have been proposed. Nuclear magnetic resonance
(NMR) studies of the interaction of synthetic peptides
corresponding to short stretches of dystrophin sequence
suggested two regions (ABS1 residues 17–26 and ABS3
residues 131–148), which might be involved in binding to
actin residues 83–117 and 350–375, respectively, on differ-
ent sides of the outer surface of the actin filament [27,28].
Fusion proteins with combinations of deletions of each of
these sites and of a highly conserved site (ABS2  residues
88–116) involved in actin binding in α-actinin, showed,
however, that actin-binding could take place with a con-
struct containing only the most N-terminal 90 residues
and that, within this sequence, the highly conserved
amino acid sequence KTFT (in single-letter amino acid
code) was not essential for binding [29]. 
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From the crystal structure, the positions of these proposed
actin-binding sites on dystrophin can be assessed. ABS1
and ABS3 are located on helix A of the CH1 and CH2
domains, respectively, whereas ABS2 is located on the
Research Article  Crystal structure of the dystrophin actin-binding domain Norwood et al. 487
Figure 5
Pathogenic missense mutations in the
dystrophin ABD. (a) Stereoview of the
environment of Leu54. (b) Stereoview of the
2Fo–Fc electron-density map in the region of
Leu54. The electron-density map is contoured
at 1.0σ. (c) Stereoview of the environment of
Ala168, Ala171 and Tyr231. The mutated
residues are coloured red, with neighbouring
hydrophobic sidechains coloured green.
(d) Schematic representation of the dystrophin
ABD sequence. The upper representation
shows the actin-binding and mutation sites
and the lower shows the exon boundaries. 
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E and F helices of CH1. These three ABSs do not form a
surface together that could dock dystrophin onto an actin
filament (Figure 6a), suggesting that a conformational
change brings the ABS regions into closer proximity to form
the binding surface. Within the ABD, CH1 appears to form
the major contacts with actin because a cleaved CH1
domain is able to bind actin, whereas an isolated CH2
domain cannot [12]. The CH2 domain does contribute to
actin binding, however, because the binding affinity of the
complete ABD is greater than that of the isolated CH1
domain [12]. It has been proposed, therefore, that the actin-
binding mechanism involves the CH1 domain forming the
principal binding surface, complemented by additional
interactions from the CH2 domain. In the crystal structure
the major region of ABS1 is buried at the dystrophin dimer
interface, whereas ABS2 and ABS3 are more solvent acces-
sible. Dimerisation of the dystrophin ABD might provide a
mechanism in which the hydrophobic surface of helix I is
kept buried from solvent until actin binding occurs. 
A model for fimbrin binding to F-actin has been proposed
on the basis of fitting the fimbrin ABD crystal structure into
an electron-difference map calculated from helical recon-
structions of fimbrin ABD decorated and undecorated actin
filaments [43]. The fimbrin ABD is modelled as the
compact crystal structure bound with ABS2, ABS3 and the
CH1–CH2-connecting region interacting with actin. ABS1
remains buried at the interface between the CH1 and CH2
domains (Figure 6b). Helical reconstructions of α-actinin
ABD decorated F-actin reveal that the ABD occupies a
bell-shaped (of dimensions 38 × 42 Å) electron-difference
density peak at the same site as fimbrin on the actin fila-
ment [44]. The structure of the utrophin ABD–F-actin
complex has also been recently determined by helical
reconstruction of electron micrographs [45]. A model of the
complex was constructed by docking the crystal structure of
a utrophin ABD into the difference density peaks with the
most satisfactory fit obtained with a model in which the rel-
ative positions of the CH1 and CH2 domains were altered
within the ABD. This rearrangement occurs at the C-termi-
nal end of the interconnecting helix, helix I. The different
conformations of the dystrophin and utrophin ABD crystal
structures result from a rotation centered about the same
region of the protein. This model of the complex places
ABS1, ABS2 and the hydrophobic face of helix I of the
utrophin ABD in contact with the actin filament. The
reconstructions of the ABDs of utrophin, fimbrin and
α-actinin ABDs reveal differences in their structures when
bound to actin, although the binding site on the filament
(between subdomains 1 and 2 of actin monomer n and sub-
domain 1 of monomer n + 2) is the same. Differences in
modes of actin-binding are also revealed by examination of
the actin filament structure in these reconstructions, with
utrophin [45] and fimbrin [46] inducing different conforma-
tional changes in the actin filament and α-actinin [44]
having no effect. These electron microscopy reconstruc-
tions, in conjunction with the crystal structures of the ABDs
from dystrophin, utrophin and fimbrin, have raised several
intriguing questions about the mechanism of actin binding
of dystrophin, and the structure of the dystrophin ABD–F-
actin complex. The dystrophin ABD binds actin in a 1:1
stoichiometry [5], and is expected to bind to the same site
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Actin-binding sites of the dystrophin and fimbrin ABDs. (a) Ribbon and
surface representations of the dystrophin ABD. The ABSs are colour-
coded: ABS1 (green), ABS2 (cyan) and ABS3 (red). The left surface
view is shown in the same orientation as the white ribbon monomer.
The right surface view is rotated 180° about the vertical axis.
(b) Ribbon representation of the fimbrin ABD. The ABSs are colour-
coded: ABS1 (green), ABS2 (cyan) and ABS3 (red). 
on the filament as utrophin, fimbrin, α-actinin and other
F-actin-binding proteins [47]. The conservation of the
domain-swapped CH1–CH2 interface between the
monomers in the dimeric dystrophin crystal structure sug-
gests that monomeric dystrophin ABD in solution might
adopt a compact globular conformation similar to that of the
fimbrin ABD crystal structure. The hydrophobic patch
formed by the I helix and C terminus, which is buried upon
dimer formation, would appear to make it unlikely that the
elongated monomeric dystrophin species exists in exactly
the same conformation in solution as found in the crystal
dimer. Because of the high level of sequence homology
between the dystrophin and utrophin ABD it would be
expected that they would bind actin in a similar way, with a
binding mechanism involving rearrangement of the CH
domains to form a binding surface. At present, however, we
cannot completely exclude an alternative model in which
the dystrophin ABD binds actin in a similar way that
fimbrin binds actin, adopting a compact monomeric struc-
ture with the ABS2 and ABS3 regions forming the majority
of the binding surface. 
Differences in modes of actin binding between dystrophin,
utrophin, fimbrin and α-actinin might be related to the dif-
ferent biological roles the proteins play within the cell, as
well as interactions with the other domains of the full-
length proteins. Dystrophin appears to be primarily a struc-
tural protein linking the actin cytoskeleton with the plasma
membrane, whereas fimbrin is involved in the bundling of
actin filaments. The identification of an actin-binding site
within the triple helical repeat region of dystrophin has led
to a model of full-length dystrophin binding actin in a side-
on fashion [48,49]. This method of binding cannot be
shared by fimbrin, which lacks the helical repeat region
and contains two ABDs that cross-link actin filaments, and
utrophin, in which this actin-binding site is missing [50].
Sequence analysis has revealed that the fimbrins are the
most divergent members of the ABD-containing protein
family and consequently have been placed into a separate
subgroup [17]. Formation of antiparallel dimers allows
α-actinin to cross-link actin filaments, illustrating another
mechanism by which CH domains are positioned and
utilised for actin-binding. The dystrophin ABD crystal
structure has revealed a different conformation to that of
utrophin and fimbrin, indicating that rearrangement of the
CH domains within the ABD is possibly an important
factor for actin binding. 
Biological implications
The X-chromosome-linked Duchenne and Becker mus-
cular dystrophies are severe progressive muscle wasting
disorders caused by pathogenic mutations that result in
the absence of functional dystrophin. Dystrophin is a
large multidomain protein localised to the sarcolemma
that appears to function primarily in a structural role,
linking the actin cytoskeleton to the extracellular matrix
via a membrane-associated glycoprotein complex. The
N-terminal actin-binding domain (ABD, residues 1–246)
of dystrophin contains two modules (called calponin
homology domains, CH1 and CH2) that are found in
other cytoskeletal proteins such as utrophin, fimbrin and
α-actinin. Two dystrophin ABDs crystallise as an
antiparallel dimer similar to utrophin, with each ABD
adopting an extended structure of two CH domains con-
nected by an α helix. In dystrophin, compared with
utrophin, a conformational change has occurred within
the ABD resulting in different orientations of the two CH
domains relative to one another, although the structures
of the individual CH domains remain very similar. The
different relative conformations of the CH domains
within the ABDs of dystrophin, utrophin and fimbrin
suggest a mechanism in which the ABDs might undergo
structural rearrangements upon actin-binding. Three
regions within the ABD have been proposed as actin-
binding sites (ABSs). Mapping these regions on the ABD
structure does not appear to present any continuous
surface that could be obviously docked onto an actin fila-
ment. Several pathogenic mutations identified in cases of
Duchenne and Becker muscular dystrophy have been
localised within the dystrophin ABD structure. Missense
mutations Leu54→Arg, Ala168→Asp, Ala171→Pro and
Tyr231→Asn are located within the hydrophobic core of
the protein fold and none of them lies within the proposed
ABS1–3. The internal location of these residues implies
that these mutations alter protein function by destabilisa-
tion of the domain fold as opposed to the substitution of
residues essential for actin binding.
Materials and methods
A construct containing the N-terminal region (residues 1–246) of dys-
trophin was generated by the polymerase chain reaction (PCR) using
Pfu DNA polymerase and a human dystrophin cDNA clone (a gift from
G Dickson, Royal Holloway College, London) as template. The cysteine
residues at positions 10 and 188 in this construct were changed to
serine residues using a PCR-based mutagenesis protocol [51]. The
resulting insert was ligated into the EcoR1 restriction sites of the pGEX
4T2 expression vector (Pharmacia) and overexpressed in
Escherichia coli BL21(DE3) cells. When the A600 from a single colony
cultured at 37°C reached 0.8, the cells were induced with 0.5 mM iso-
propyl-β-D-thiogalactoside (IPTG) at 25°C. After 3 h, cells were col-
lected and suspended in a buffer containing 140 mM NaCl, 2.7 mM
KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4 (PBS) and the protease
inhibitor cocktail (Complete Boehringer Mannheim) and sonicated at
4°C. The resulting lysed cell suspension was centrifuged at 10,500 g
(8,000 rpm in Sorvall GSA rotor) for 20 min and the lysate loaded onto
a 3 ml glutathione-Sepharose 4B affinity matrix column (Pharmacia).
After washing with 3 × 10 bed volumes of PBS buffer, the column
matrix was sealed and incubated with 500 units of thrombin protease
(Pharmacia) dissolved in 5 mls of PBS for 16 h at 4°C to cleave the
dystrophin portion from the N-terminal glutathione-S-transferase
domain. The flow through after thrombin digestion containing the
expressed dystrophin was immediately loaded onto a Sephacryl HR
200 gel-filtration column (80 × 2.6 cm) equilibrated in 20 mM Tris-Cl
pH 8.0, 1 mM DTT, 50 mM NaCl for further purification and to remove
the thrombin. The peak fractions containing the dystrophin ABD were
pooled, concentrated in a Centricon-10 concentrator (Amicon) and
dialysed against a buffer containing 5 mM Tris-Cl pH 8.0 and 1 mM
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DTT. Following dialysis, the sample was centrifuged at 100,000 rpm
for 20 min in a Beckman Optima TL benchtop ultracentrifuge to remove
any aggregated material. Crystals were obtained from 5 µl hanging
drops formed by mixing equal volumes of dystrophin N terminus at a
concentration of 10 mg/ml with 1.55 M ammonium formate buffered by
0.1M HEPES pH 7.4 and equilibrated at 18°C against reservoirs of
1.55M ammonium formate, 0.1M HEPES pH 7.4. Crystals appeared
after three days and grew typically to 200 × 100 × 20 µM in two weeks. 
A single thin plate-like crystal, of approximate dimensions
200 × 100 × 20 µM was frozen in a loop with 25%(v/v) glycerol in the
crystallisation mother liquor as cryoprotectant. A 2.6 Å data set was col-
lected on the frozen crystal using a MAR345 image plate with 1.0 Å syn-
chrotron radiation at the XRDI beamline, Elettra, Italy. The crystal was
found to be triclinic with cell dimensions a = 59.69 Å, b = 79.33 Å,
c = 81.95 Å, α = 61.08°, β = 78.22°, γ = 70.54°, and exhibited a mosaic-
ity of 1.45°. Cell volume calculations suggested that four molecules were
present in the asymmetric unit with a solvent content of 52%. The diffrac-
tion intensities were integrated with DENZO, and scaled and merged
with SCALEPACK [52]. Data quality statistics are provided in Table 1. 
The structure of the N-terminal actin-binding region of dystrophin was
solved by molecular replacement. The search model was derived from
the crystal structure of the utrophin dimer [25], and consisted of a CH1
domain from one monomer (ACH1, residues A31–A142) and a CH2
domain from the other (BCH2, residues B153–B256). Sidechains were
truncated to common atoms at substitution sites between the dys-
trophin and utrophin sequences. Molecular replacement calculations
using the utrophin monomer (ACH1 and ACH2, residues A31–A256)
or dimer proved unsuccessful. All molecular replacement calculations
were performed using the program AMORE [53]. The orientations of the
four molecules were clearly distinguishable from the noise of the rotation
function, with the top four peaks having peak-height/σ values of 16.0,
15.1, 14.5 and 13.6 with the next highest peak of 10.2. The four solu-
tions were consistently the top peaks when the rotation function was
calculated with a Patterson integration radius varying between 20 and
28 Å (data in the resolution range 8.0–3.5 Å). The solutions were
related by twofold symmetry operations consistent with those obtained
from a self-rotation function calculated using GLRF [54]. These orienta-
tions resulted in an unambiguous solution to the translation function
(calculated with data in the resolution range 8–3.5 Å) giving an initial
model of correlation coefficient 0.43 and R factor 0.47 (for data in the
resolution range 8.0–3.5 Å). Rigid-body refinement conducted with
REFMAC [55] improved the model R = 0.466, Rfree = 0.473 (for data in
the resolution range 20.0–2.6 Å, and with Rfree calculated from 5% of
data, 1797 reflections, omitted from all refinement). Initially each
CH1A–CH2B domain-swapped search model was refined as a rigid
unit, followed by refinement of the eight CH domains individually. Model
rebuilding was carried out in O [56] using maps calculated directly from
REFMAC coefficients and also maps averaged using the RAVE algo-
rithms [57]. Positive difference density was clearly visible for sidechains
at substitution sites, as well as the linker region between the CH1 and
CH2 domains, regions of the structure that were not included in the
search model. The addition of the residues in the linker region resulted
in a model consisting of two dimers in the asymmetric unit. Solvent mol-
ecules were added to the model if a positive 3σ peak existed in the
Fo–Fc difference map in a position in which chemically sensible hydro-
gen bonds could be made. Whether similar peaks occurred near NCS-
related chains and also the position of solvent atoms in the homologous
structures was also taken into account. There were 74 solvent atoms
included in total. The model was refined by cycles of rebuilding followed
by maximum-likelihood refinement conducted in REFMAC. Initially a
Babinet estimation for the bulk-solvent contribution was employed,
which was later replaced by a mask-derived bulk solvent correction cal-
culated with X-PLOR [58]. Very tight NCS restraints were enforced
during the refinement and tightly restrained individual isotropic tempera-
ture factors were refined during the final stages. The refinement con-
verged to yield a final model with R factor = 0.232 (and free
Rfree = 0.268) for all data 20.0–2.6 Å. Further model statistics are pre-
sented in Table 2. The figures were prepared with BOBSCRIPT [59],
RASTER3D [60], ALSCRIPT [61] and GRASP [62]. The ABD
sequences were aligned with CLUSTALW [63]. 
Accession numbers
Coordinates have been deposited in the PDB with accession code 1DXX.
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